Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Historical dividends Dividends
All dividend metrics All metricsIn 2021, Percheron Therapeutics Aktie has already paid €0.0732 in dividends. The last payout was in July 2021.
Financials
In the last year, Percheron Therapeutics Aktie had revenue of €1.85m and net profit of -€7.41m
| (EUR) | 2024 | YoY |
|---|---|---|
| Revenue | 1.85m | 91.36% |
| Gross profit | 1.81m | 99.37% |
| Net profit | -7.41m | 6.68% |
| EBITDA | -7.4m | 6.63% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €17.89m |
Number of shares | 1.64bn |
52-week high/low | €0.0684 - €0.00911 |
| Dividends | No |
Beta | 0.87 |
P/E ratio | -0.73 |
PEG ratio | -0.01 |
P/B ratio | 0.55 |
P/S ratio | 0.00 |
Company profile
Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.
| Name | Percheron Therapeutics Aktie |
| CEO | James Garner MBA |
| Headquarters | Toorak,
vic Australia |
| Website | |
| IPO | 26/12/2023 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Pnk | ATHJF |
Frankfurt | AWY0.F |
München | AWY0.MU |